UNITED STATES
NUCLEAR REGULATORY COMMISSION
REGION IV
611 RYAN PLAZA DRIVE, SUITE 400
ARLINGTON, TEXAS 76011-4005

April 25, 2007

Eastern Idaho Health Services, Inc.
dba Eastern Idaho Regional Medical Center
ATTN: James Neeley, M.D.
Radiation Safety Officer
P.O. Box 2077
Idaho Falls, ID 83403-2077

SUBJECT: LICENSE AMENDMENT

Please find enclosed Amendment No. 23 to NRC License No. 11-27346-01 **removing David Madden, M.D., as an authorized user from this license and adding Steven J. Todd, M.D., as an authorized user for 10 CFR 35.300 and 35.400 uses.** An environmental assessment for this licensing action is not required, since this action is categorically excluded under 10 CFR 51.22(c)(14)(iv). You should review the enclosed document carefully and be sure that you understand all conditions. If there are any errors or if you have any questions, please contact me at 817-860-8189.

NRC expects licensees to conduct their programs with meticulous attention to detail and a high standard of compliance. Because of the serious consequences to employees and the public that can result from failure to comply with NRC requirements, you must conduct your radiation safety program according to the conditions of your NRC license, representations made in your license application, and NRC regulations. In particular, note that you must:

1. Operate by NRC regulations 10 CFR Part 19, "Notices, Instructions and Reports to Workers: Inspection and Investigations," 10 CFR Part 20, "Standards for Protection Against Radiation," and other applicable regulations.

2. Notify NRC in writing of any change in mailing address.

3. By 10 CFR 30.36(d) and/or license condition, notify NRC, promptly, in writing, and request termination of the license:

   a. When you decide to terminate all activities involving materials authorized under the license whether at the entire site or any separate building or outdoor area;

   b. If you decide not to acquire or possess and use authorized material; or

   c. When no principal activities under the license have been conducted for a period of 24 months.

4. In accordance with 10 CFR 35.14, notify the NRC no later than 30 days after:

   a. The date that the licensee permits an individual to work as an authorized user, an authorized nuclear pharmacist or an authorized medical physicist under 10 CFR 35.13(b)(1) through (b)(4);

b. An authorized user, an authorized nuclear pharmacist, a Radiation Safety Officer, or an authorized medical physicist permanently discontinues duties under the license or has a name change;

c. The licensee's mailing address changes;

d. The licensee's name changes, but the name change does not constitute a transfer of control of the license as described in 10 CFR 30.34(b); or

e. The licensee has added to or changed the areas of use identified in the application or on the license where byproduct material is used in accordance with either 35.100 or 35.200.

5. Request and obtain a license amendment before you:

a. Change Radiation Safety Officers;

b. Order byproduct material in excess of the amount, radionuclide or form authorized on the license;

c. Add or change the areas or address(es) of use identified in the license application or on the license, except for areas of use where byproduct material is used only in accordance with either 10 CFR 35.100 or 35.200; or

d. Change the name or ownership of your organization.

6. Submit a complete renewal application or termination request at least 30 days before the expiration date on your license. You will receive a reminder notice approximately 90 days before the expiration date. Possession of radioactive material after your license expires is a violation of NRC regulations.

In addition, please note that NRC Form 313 requires the applicant, by signature, to verify that the applicant understands that all statements contained in the application are true and correct to the best of the applicant's knowledge. The signatory for the application should be the licensee or certifying official rather than a consultant. Since the NRC also accepts a letter requesting amendment of an NRC license, the signatory for such a request should also be the licensee or certifying official rather than a consultant.

NRC will periodically inspect your radiation safety program. Failure to conduct your program according to NRC regulations, license conditions, and representations made in your license application and supplemental correspondence with NRC may result in enforcement action against you. This could include issuance of a notice of violation; imposition of a civil penalty; or an order suspending, modifying, or revoking your license as specified in the NRC Enforcement Policy. The NRC Enforcement Policy is available on the following internet address: http://www.nrc.gov/what-we-do/regulatory/enforcement/enforc-pol.pdf.

The NRC no longer publishes the NRC Rules and Regulations loose leaf supplements. However, an electronic version of the NRC's regulations is available on the NRC Web site at www.nrc.gov. To view these regulations, highlight "Electronic Reading Room" and choose "Regulations" on the drop down menu. An electronic version of the NUREG-1556 Series publications is also available on the NRC Web site. To view these guidance documents, highlight "Electronic Reading Room"; choose "All Collections" on the drop down menu; choose "NUREGS (NRC Reports)"; and select "Publications Prepared by the NRC Staff". Then, choose "NUREG-1556" from the table and select the appropriate volume(s) for your license type.

In accordance with 10 CFR 2.390 of the NRC's "Rules of Practice," a copy of this letter and its enclosure will be available electronically for public inspection in the NRC Public Document Room or from the NRC's document system (ADAMS). ADAMS is accessible from the NRC Web site at http://www.nrc.gov/reading-rm/adams.html.

Thank you for your cooperation.

Sincerely,

/RA/

Roberto J. Torres, Senior Health Physicist
Nuclear Materials Licensing Branch

Docket: 030-32290
License: 11-27346-01
Control: 471330

Enclosure: As stated

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee	In accordance with letter dated March 27, 2007
1. Eastern Idaho Health Services, Inc. dba Eastern Idaho Regional Medical Center	3. License number 11-27346-01 is amended in its entirety to read as follows:
2. P.O. Box 2077 Idaho Falls, Idaho 83403-2077	4. Expiration date May 31, 2013
	5. Docket No. 030-32290 Reference No.

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license
A. Any byproduct material permitted by 10 CFR 35.100	A. Any	A. As needed
B. Any byproduct material permitted by 10 CFR 35.200	B. Any	B. As needed
C. Any byproduct material permitted by 10 CFR 35.300	C. Any	C. 400 millicuries
D. Any byproduct material identified by 10 CFR 35.400	D. Sealed sources (Medi Physics, Inc. Model 6711, Best Medical International, Inc. Model 2300 series, IsoStar Texas, Inc. Model IS-125 series, North American Scientific Model MED 3631, BEBIG GmbH Model I25.S06, International Brachytherapy Model 125IL, Implant Sciences Corporation Model 3500, Draximage, Inc. Model LS-1, Mills Biopharmaceuticals, Inc. Models I-125SL and I-125SH, IsoAid LLC Model IAI-125A, Isotron Isotopentechnik Model 130.002, Isotope Products Laboratories Model 67-800 series, 3M Model 6500 series, or AEA Technology Model CDC.T1 J series)	D. 1,300 millicuries total

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License Number
11-27346-01

Docket or Reference Number
030-32290

Amendment No. 23

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license
E. Gadolinium-153	E. Sealed sources (North American Scientific, Inc. Model 3601 or Du Pont Merck Pharmaceuticals Company Model NES-8412)	E. 300 millicuries per housing, total possession 1,200 millicuries
F. Iodine-125 permitted by 10 CFR 1000	F. Liquid as Proxima Therapeutics, Inc. Iotrex™	F. 5 curies

9. Authorized use

A. Any uptake, dilution and excretion study permitted by 10 CFR 35.100.
B. Any imaging and localization study permitted by 10 CFR 35.200.
C. Any use permitted by 10 CFR 35.300.
D. Any manual brachytherapy procedure permitted by 10 CFR 35.400 and, for cesium-137, calibration of licensee's survey meters and personnel dosimeters.
E. For use in the ADAC Laboratories Models 2146-3536 and 2146-3440 transmission line source housing.
F. For brachytherapy use in the Proxima Therapeutics' GliaSite® Radiotherapy system permitted by 10 CFR 35.1000.

CONDITIONS

10. Licensed material may be used or stored at the licensee's facilities located at 3100 Channing Way, Idaho Falls, Idaho.

11. The Radiation Safety Officer for this license is James Neeley, M.D.

12. Licensed material is only authorized for use by, or under the supervision of:

A. Individuals permitted to work as an authorized user, authorized nuclear pharmacist, and/or authorized medical physicist in accordance with 10 CFR 35.13 and 35.14.

B. The following individuals are authorized users for medical use:

Authorized Users	Material and Use
Kevin C. Funk, M.D.	35.100; 35.200; 35.300; Gadolinium-153 for patient attenuation correction
James Neeley, M.D.	35.100; 35.200; 35.300; Gadolinium-153 for patient attenuation correction

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License Number
11-27346-01

Docket or Reference Number
030-32290

Amendment No. 23

Authorized Users	Material and Use
James P. Edlin, M.D.	35.100; 35.200; 35.300; Gadolinium-153 for patient attenuation correction
John D. Chambers, Jr., M.D.	35.200; Gadolinium-153 for patient attenuation correction
John J. Strobel, M.D.	35.100; 35.200; 35.300; Gadolinium-153 for patient attenuation correction
James Harris, M.D.	35.100; 35.200; Gadolinium-153 for patient attenuation correction
James Schmutz, M.D.	35.100; 35.200; Gadolinium-153 for patient attenuation correction
Michael C. Biddulph, M.D.	35.100; 35.200; 35.300; Gadolinium-153 for patient attenuation correction
Michael T. Callaghan, M.D.	35.300; 35.400; Gadolinium-153 for patient attenuation correction
Calvin McAllister, M.D.	35.300; 35.400; Gadolinium-153 for patient attenuation correction; 35.1000 only Iodine-125 Gliasite RTS System
David R. Warden III, M.D.	35.100; 35.200; Gadolinium-153 for patient attenuation correction
Douglas U. Blank, M.D.	35.200; Gadolinium-153 for patient attenuation correction
Steven D. Smith, M.D.	35.100; 35.200; oral administration of sodium iodide I-131; Gadolinium-153 for patient attenuation correction
Robert D. Greally, M.D.	35.100; 35.200; Gadolinium-153 for patient attenuation correction
Peter Lead Vance, M.D.	35.100; 35.200; Gadolinium-153 for patient attenuation correction
Thomas J. Maley, M.D.	35.200; Gadolinium-153 for patient attenuation correction
Steven J. Todd, M.D.	35.300; 35.400

13. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d) for establishing decommissioning financial assurance.

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License Number
11-27346-01

Docket or Reference Number
030-32290

Amendment No. 23

14. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.

A. Application dated December 26, 2002 (ML030300013)
B. Letter dated May 27, 2003 (ML031681396)
C. Letter dated May 12, 2005 (ML051710487)
D. Letter dated June 7, 2005 (ML051710487)
E. Letter dated August 18, 2005 (ML052310584)
F. Letter dated March 22, 2006 (ML061000533)
G. Facsimile dated April 6, 2006 (ML061000533)
H. Letter dated September 26, 2006 (ML070250093)

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

/RA/

Date: April 25, 2007

By: _____

Roberto J. Torres, Senior Health Physicist
Nuclear Materials Licensing Branch
Region IV
Arlington, Texas 76011